Patents Issued in January 24, 2019
  • Publication number: 20190023706
    Abstract: The present invention relates to an improved process for the preparation of Valacyclovir or pharmaceutically acceptable salts thereof, which comprises reaction of amine-protected Valacyclovir or its salt with deprotecting agent in a continuous flow reactor.
    Type: Application
    Filed: February 24, 2017
    Publication date: January 24, 2019
    Applicant: Aurobindo Pharma Ltd
    Inventors: Sandeep Jain, Komel Ansari, Subramanyam Maddala, Sivakumaran Meenakshisundaram
  • Publication number: 20190023707
    Abstract: Compound (I), and pharmaceutically acceptable salts thereof, are inducers of human interferon. Certain discrete and particular dosages of Compound (I) may be particularly useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions, for example allergic rhinitis and allergic asthma.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventors: Claire Louise AMBERY, Christopher David EDWARDS
  • Publication number: 20190023708
    Abstract: Purine scaffold Hsp90 inhibitors are useful in therapeutic applications and as radioimaging ligands.
    Type: Application
    Filed: May 18, 2018
    Publication date: January 24, 2019
    Inventor: Gabriela Chiosis
  • Publication number: 20190023709
    Abstract: Compounds of formula (I): where R1, R2, R3, R4a, R4b, R5, R6 and R7 are defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.
    Type: Application
    Filed: September 12, 2018
    Publication date: January 24, 2019
    Inventors: Lloyd F. Mackenzie, Curtis Harwig, David Bogucki, Jeffery R. Raymond, Jeremy D. Pettigrew
  • Publication number: 20190023710
    Abstract: The present invention provides novel compounds of any one of Formulae (I)-(IV), and pharmaceutical compositions thereof. Also provided are particles (e.g., nanoparticles) comprising compounds of any one of Formulae (I)-(IV) and pharmaceutical compositions thereof that are mucus penetrating. The invention also provides methods and kits for using the inventive compounds, and pharmaceutical compositions thereof, for treating and/or preventing diseases associated with abnormal or pathological angiogenesis and/or aberrant signaling of a growth factor signaling pathway (e.g., vascular endothelial growth factor (VEGF), such as proliferative diseases (e.g., cancers, benign neoplasms, inflammatory diseases, autoimmune diseases) and ocular diseases (e.g., macular degeneration, glaucoma, diabetic retinopathy, retinoblastoma, edema, uveitis, dry eye, blepharitis, and post-surgical inflammation) in a subject in need thereof.
    Type: Application
    Filed: June 21, 2018
    Publication date: January 24, 2019
    Inventors: Winston Zapanta Ong, Pawel Wojciech Nowak, Ben C. Askew, Andrew Good
  • Publication number: 20190023711
    Abstract: The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.
    Type: Application
    Filed: July 27, 2018
    Publication date: January 24, 2019
    Inventors: Hamid R. Hoveyda, Guillaume Dutheuil, Graeme Lovat Fraser, Marie-Odile Roy, Mohamed El Bousmaqui, Frederic Batt
  • Publication number: 20190023712
    Abstract: The present application falls within the field of drug synthesis, and in particular, the present application relates to a method for preparing ruxolitinib, and a method for preparing the intermediate and relevant intermediates used. The method comprises reacting a compound of formula II with a compound of formula IV or a salt thereof to obtain a compound of formula III, and then subjecting the compound of formula III to an acyl halogenation reaction, an amidation reaction, and a reaction dehydrating an amide to form a cyano group or removing the protecting group to prepare ruxolitinib. The method has the characteristics of brief steps, a high stereoselectivity, a high utilization ratio of atoms, mild reaction conditions and convenient post treatment. The method avoids using expensive asymmetric reaction catalysts, and is suitable for industrial production.
    Type: Application
    Filed: December 29, 2016
    Publication date: January 24, 2019
    Inventors: Xiquan Zhang, Aiming Zhang, Zhou Zhou, Leilei Yang, Huadong Yao, Xueyan Zhu, Hubo Wang
  • Publication number: 20190023713
    Abstract: The invention relates to compounds having the structure of formula (I) which can be used for the treatment of or against influenza infections.
    Type: Application
    Filed: January 5, 2017
    Publication date: January 24, 2019
    Inventors: Jérôme Émile Georges GUILLEMONT, Wendy Mia Albert BALEMANS, David Craig MC GOWAN, Magali Madeleine Simone MOTTE, David Francis Alain LANÇOIS, Emilie Marie LAMBERT
  • Publication number: 20190023714
    Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
    Type: Application
    Filed: February 7, 2018
    Publication date: January 24, 2019
    Inventors: Ayman ALLIAN, Jayanthy JAYANTH, Mohamed-Eslam F. MOHAMED, Mathew M. MULHERN, Lars Fredrick NORDSTROEM, Ahmed A. OTHMAN, Michael J. ROZEMA, Lakshmi BHAGAVATULA, Patrick J. MARROUM, Peter T. MAYER, Ahmad Y. SHEIKH, Thomas B. BORCHARDT
  • Publication number: 20190023715
    Abstract: The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.
    Type: Application
    Filed: September 27, 2018
    Publication date: January 24, 2019
    Inventors: Zehong WAN, Xiaomin ZHANG, Jian WANG, Matthew Robert SENDER, Eric Steven MANAS, Raphael Anthony RIVERO, Joseph E PERO, Christopher Ernst NEIPP, Vipulkumar Kantibhai PATEL
  • Publication number: 20190023716
    Abstract: Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.
    Type: Application
    Filed: March 15, 2018
    Publication date: January 24, 2019
    Inventors: Robert Zahler, Zhenwei Cai, Zhixing Wu, James E. Vath
  • Publication number: 20190023717
    Abstract: In one aspect, the present invention provides novel derivatives of trioxacarin analogs of the formula (I) wherein the variables are as defined herein. The application also provides compositions, methods of treatment, and methods of synthesis thereof.
    Type: Application
    Filed: December 18, 2015
    Publication date: January 24, 2019
    Applicant: WILLIAM MARSH RICE UNIVERSITY
    Inventors: Kyriacos C NICOLAOU, Quan CAI
  • Publication number: 20190023718
    Abstract: The present invention relates to novel crystalline forms of dolutegravir, process for its preparation and pharmaceutical composition comprising them.
    Type: Application
    Filed: August 19, 2016
    Publication date: January 24, 2019
    Inventors: Ram THAIMATTAM, Rajesh EDUPUGANTI, Venkata Sunil Kumar INDUKURI, Srihari Raju KALIDINDI, Satyanarayana CHAVA
  • Publication number: 20190023719
    Abstract: Disclosed are compounds of Formula (I) wherein: the two dotted lines represent either two single or two double bonds; Q is: R1 is F, Cl, —CN, or —CH3; R2 is Cl or —CH3; R3 is —C(CH3)2OH or —CH2CH2OH; Ra is H or —CH3; each Rb is independently F, Cl, —CH3, and/or —OCH3; and n is zero, 1, or 2. Also disclosed are methods of using such compounds as inhibitors of Bruton's tyrosine kinase (Btk), and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.
    Type: Application
    Filed: September 25, 2018
    Publication date: January 24, 2019
    Inventors: Douglas G. Batt, Myra Beaudoin Bertrand, George V. De Lucca, Michael A. Galella, Soo Sung Ko, Charles M. Langevine, Qingjie Liu, Qing Shi, Anurag S. Srivastava, Joseph A. Tino, Scott Hunter Watterson
  • Publication number: 20190023720
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: September 5, 2018
    Publication date: January 24, 2019
    Applicant: Amgen Inc.
    Inventors: Sean P. BROWN, Yunxiao LI, Mike Elias LIZARZABURU, Brian S, LUCAS, Nick A. PARAS, Joshua TAYGERLY, Marc VIMOLRATANA, Xianghong WANG, Ming YU, Manuel ZANCANELLA, Liusheng ZHU, Ana GONZALEZ BUENROSTRO, Zhihong LI
  • Publication number: 20190023721
    Abstract: Gold(III) complexes containing mixed ligands. A method of treating cancer with these complexes is disclosed. The complexes are cytotoxic to prostate, breast, ovarian, and Hodgkin lymphoma cancer cell lines. These complexes were either more potent than cisplatin or had similar potency to cisplatin.
    Type: Application
    Filed: July 20, 2017
    Publication date: January 24, 2019
    Applicant: King Fahd University of Petroleum and Minerals
    Inventors: Anvar Husain Abdul Kadir ISAB, Muhammad Altaf
  • Publication number: 20190023722
    Abstract: PSMA-targeted PET/SPECT agents for imaging PSMA-positive cancer and or tumor neovasculature and PSMA-targeted radiotherapeutic agent for the treatment of PSMA-positive cancer or tumor neovasculature are disclosed. Methods of imaging PSMA expressing tumors, or cells and kits also are disclosed.
    Type: Application
    Filed: March 14, 2016
    Publication date: January 24, 2019
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: MARTIN G. POMPER, RONNIE C. MEASE, SANGEETA RAY
  • Publication number: 20190023723
    Abstract: The present invention relates to compositions comprising at least one hydridosilane of the generic formula SinHm with n?5 and m=(2n) and (2n+2) and at least one compound of the formula HnB (OR)3-n with R=C1-C10-alkyl, C6-C10-aryl, C7-C14-aralkyl, halogen, n=0, 1, 2, to processes for preparation thereof and use thereof.
    Type: Application
    Filed: December 6, 2016
    Publication date: January 24, 2019
    Applicant: Evonik Degussa GmbH
    Inventors: Stephan HERRMANN, Odo WUNNICKE, Matthias PATZ, Miriam Deborah MALSCH, Harald STUEGER
  • Publication number: 20190023724
    Abstract: The present invention relates to process for preparation of tavaborole with high purity. The present invention relates to method of assessing the purity of tavaborole.
    Type: Application
    Filed: January 12, 2017
    Publication date: January 24, 2019
    Inventors: Srinivasan Subramanian Kuduva, Rajender N/A, Mahendra CHORAGHE, Samir NAIK, Shekhar Bhaskar BHIRUD
  • Publication number: 20190023725
    Abstract: The present invention relates to a modifier, and more particularly, to a modifier including a compound represented by Formula 1, a method of preparing the same, and a modified conjugated diene-based polymer including the same. The present invention also provides a modifier exhibiting excellent dispersibility via hydrogen bonding with an inorganic filler when mixed therewith, a method of preparing the same, a modified conjugated diene-based polymer modified using the modifier and thus exhibiting excellent processability, high tensile strength, high wear resistance, low rolling resistance, and high wet skid resistance, and a method of preparing the modified conjugated diene-based polymer.
    Type: Application
    Filed: September 5, 2017
    Publication date: January 24, 2019
    Applicant: LG Chem, Ltd.
    Inventors: Min Sik Mun, No Ma Kim, Da Won Chai, Ho Young Lee
  • Publication number: 20190023726
    Abstract: The purpose of the present invention is to provide a protecting group which improves the solubility of a compound having a functional group protected with the protecting group in an organic solvent and which is easily separated and purified after a reaction with avoiding solidification or insolubilization.
    Type: Application
    Filed: August 25, 2016
    Publication date: January 24, 2019
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Shinya YANO, Yuki WAKASUGI, Yosuke IWANAGA
  • Publication number: 20190023727
    Abstract: A method for preparing a 3-((2S,5S)-4-methylene-5-(3-oxopropyl)tetrahydrofuran-2-yl)propanol derivative by a simple process with high yields, and an intermediate useful for the method.
    Type: Application
    Filed: January 13, 2017
    Publication date: January 24, 2019
    Applicant: YONSUNG FINE CHEMICAL CO., LTD.
    Inventors: Hyun Ik SHIN, Kee Young LEE, Changyoung OH
  • Publication number: 20190023728
    Abstract: Provided are a polyhedral oligomeric silsesquioxane and a preparation method thereof, more particularly, a polyhedral oligomeric silsesquioxane itself which has a low refractive property and enables formation of a coating layer with excellent chemical and mechanical properties, and provides excellent adhesive strength for the surfaces of various substrates, and a preparation method thereof.
    Type: Application
    Filed: March 9, 2017
    Publication date: January 24, 2019
    Applicant: LG Chem, Ltd.
    Inventors: Ji Young Choi, Dai Seung Choi, Young Jee Song
  • Publication number: 20190023729
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an aryl, heteroaryl or heterocycle (R32) are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade at an early and essential point in the alternative complement pathway, and reduce factor D's ability to modulate the classical and lectin complement pathways. The inhibitors of factor D described herein are capable of reducing the excessive activation of complement, which has been linked to certain autoimmune, inflammatory, and neurodegenerative diseases, as well as ischemia-reperfusion injury and cancer.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Applicant: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Venkat Rao Gadhachanda, Qiuping Wang, Godwin Pais, Akihiro Hashimoto, Dawei Chen, Xiangzhu Wang, Atul Agarwal, Milind Deshpande, Avinash S. Phadke
  • Publication number: 20190023730
    Abstract: Hsp90 C-terminal inhibitors and pharmaceutical compositions containing such compounds are provided. The compounds of the disclosure are useful for the treatment and/or prevention of neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Application
    Filed: June 26, 2018
    Publication date: January 24, 2019
    Inventors: Brian S.J. BLAGG, Bhaskar Reddy KUSUMA, Teather SUNDSTROM
  • Publication number: 20190023731
    Abstract: The invention described herein relates to processes for preparing ketolide antibacterial agents. In particular, the invention relates to intermediates and processes for preparing ketolides that include a 1,2,3-triazole substituted side chain.
    Type: Application
    Filed: February 20, 2018
    Publication date: January 24, 2019
    Inventor: David Eugene PEREIRA
  • Publication number: 20190023732
    Abstract: The present invention relates to novel oligonucleotides comprising at least one locked nucleoside and at least one triazole inter-nucleoside linkage.
    Type: Application
    Filed: July 17, 2018
    Publication date: January 24, 2019
    Inventors: Tom BROWN, Afaf Helmy EL-SAGHEER, Pawan KUMAR
  • Publication number: 20190023733
    Abstract: The present invention relates to compounds characterized by having a structure according to the following Formula I: or a pharmaceutically acceptable salt thereof. Compounds of the present invention are useful for the treatment or prevention of HIV.
    Type: Application
    Filed: January 19, 2017
    Publication date: January 24, 2019
    Inventor: Brian Alvin JOHNS
  • Publication number: 20190023734
    Abstract: Disclosed herein are formulations, substrates, and arrays for amino acid and peptide synthesis on microarrays. In certain embodiments, methods for manufacturing and using the formulations, substrates, and arrays including one-step coupling, e.g., for synthesis of peptides in a C?N orientation are disclosed. In some embodiments, disclosed herein are formulations and methods for high efficiency coupling of biomolecules to a substrate.
    Type: Application
    Filed: June 26, 2018
    Publication date: January 24, 2019
    Inventor: Vasanth Jayaraman
  • Publication number: 20190023735
    Abstract: The invention discloses a separation matrix which comprises a plurality of separation ligands, defined by the formula R1-L1-N(R3)-L2-R, immobilized on a support, wherein R1 is a five- or six-membered, substituted or non-substituted ring structure or a hydroxyethyl or hydroxypropyl group; L1 is either a methylene group or a covalent bond; R2 is a five-or six-membered, substituted or non-substituted ring structure; L2 is either a methylene group or a covalent bond; R3 is a methyl group; and wherein if R1 is a hydroxyethyl group and L1 is a covalent bond, R2 is a substituted aromatic ring structure or a substituted or non-substituted aliphatic ring structure.
    Type: Application
    Filed: August 29, 2018
    Publication date: January 24, 2019
    Applicant: GE Healthcare BioProcess R&D AB
    Inventors: Jean-Luc Maloisel, Gustav Rodrigo, Bjorn Noren, Virendra Kumbhar
  • Publication number: 20190023736
    Abstract: The present invention provides a method for purifying a protein, comprising: providing a solution containing a monomer and aggregates of the protein of interest; a purification step of removing the aggregates of the protein of interest using a cation-exchange chromatographic support media to obtain a purified solution of the monomer, the cation-exchange chromatographic support media comprising at least one type of weak cation-exchange group and having a cation-exchange group density higher than 30 mmol/L; and a virus removal step of removing viruses from the purified solution using a virus removal membrane having a virus logarithmic reduction value of 3 or more.
    Type: Application
    Filed: January 17, 2017
    Publication date: January 24, 2019
    Applicant: ASAHI KASEI MEDICAL CO., LTD.
    Inventors: Yoshiro YOKOYAMA, Hiroki TANIGUCHI
  • Publication number: 20190023737
    Abstract: Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.
    Type: Application
    Filed: March 8, 2018
    Publication date: January 24, 2019
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Jeremy Travins, Zhenwei Cai, Dawei Cui, Ding Zhou
  • Publication number: 20190023738
    Abstract: Disclosed herein are methods and compositions for the treatment and/or prevention of diseases or conditions comprising administration of phenazine-3-one and/or phenothiazine-3-one derivatives, analogues, or pharmaceutically acceptable salts thereof, alone or in combination with one or more active agents (e.g., an aromatic-cationic peptide). The present technology provides compositions related to aromatic-cationic peptides linked to phenazine-3-one or phenothiazine-3-one derivatives and uses of the same. In some embodiments, the aromatic-cationic peptide comprises D-Arg-2?6?-Dmt-Lys-Phe-NH2.
    Type: Application
    Filed: February 14, 2018
    Publication date: January 24, 2019
    Inventor: D. Travis Wilson
  • Publication number: 20190023739
    Abstract: The present invention provides peptides containing a structure in which a portion of the dominant negative peptide of BIG3 which inhibits the interaction between BIG3 and PHB2 is substituted with stapling structure(s). Peptides of the present invention have excellent cell growth inhibitory actions. Furthermore, their cell growth inhibitory actions continue for a longer time than the actions of peptides without stapling structures. Therefore, these peptides have features suitable for clinical applications in cancer therapy.
    Type: Application
    Filed: January 16, 2017
    Publication date: January 24, 2019
    Applicants: TOKUSHIMA UNIVERSITY, ONCOTHERAPY SCIENCE, INC.
    Inventors: TOYOMASA KATAGIRI, TAKASHI MIYAMOTO, RIE HAYASHI
  • Publication number: 20190023740
    Abstract: Provided herein are compounds that inhibit a binding interaction between a ? integrin and a G protein subunit, as well as compositions, e.g., pharmaceutical compositions, comprising the same, and related kits. In some embodiments, the compound is an antibody or antibody analog, and, in other embodiments, the compound is a peptide or peptide analog. Also provided are methods of using the compounds, including methods of treating or preventing a medical condition, such as stroke, heart attack, cancer, or inflammation.
    Type: Application
    Filed: May 22, 2018
    Publication date: January 24, 2019
    Inventor: Xiaoping Du
  • Publication number: 20190023741
    Abstract: The present invention provides a novel molecule that catalyzes a hydrolysis reaction and is different from enzyme proteins. The catalytic peptide according to the present invention is a catalytic peptide that catalyzes a hydrolysis reaction, including at least one peptide selected from the group consisting of the following peptides (A1) to (A4): (A1) a peptide consisting of Box A and at least one of an upstream region and a downstream region therefrom in a Tob/BTG protein; (A2) a peptide consisting of a partial region of the peptide (A1); (A3) a peptide that consists of an amino acid sequence obtained by deletion, substitution, addition, and/or insertion of one or more amino acids in an amino acid sequence of the peptide (A1) or (A2) and has hydrolysis activity; and (A4) a peptide consisting of an amino acid sequence with a sequence identity of at least 85% to the amino acid sequence of the peptide (A1) or (A2) and having hydrolysis activity.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Inventors: Toshifumi AKIZAWA, Tadashi YAMAMOTO
  • Publication number: 20190023742
    Abstract: Provided is a supramolecular polypeptide comprising alternating repeats of crystallite-forming subsequences and amorphous subsequences. The crystallite-forming subsequences form crystallites comprising stacks of one or more ?-sheets and the amorphous subsequences form a network of hydrogen bonds. The supramolecular polypeptides are capable of exhibiting self-healing behavior.
    Type: Application
    Filed: July 24, 2018
    Publication date: January 24, 2019
    Inventors: Melik Demirel, Benjamin Allen, Huihun Jung
  • Publication number: 20190023743
    Abstract: Drug-polymer chemotherapeutics are provided having improved therapeutic efficacy and reduced dose-limiting toxicity. Methods are also provided for modulating the architecture, pharmacokinetics and biodistribution of drug-polymers and for reducing the dependence of transition temperature on concentration for drug-polymers.
    Type: Application
    Filed: August 8, 2018
    Publication date: January 24, 2019
    Inventors: Ashutosh Chilkoti, John A. MacKay, Matthew R. Dreher
  • Publication number: 20190023744
    Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.
    Type: Application
    Filed: July 19, 2018
    Publication date: January 24, 2019
    Inventors: Johannes Petrus Maria LANGEDIJK, Lucy RUTTEN, Nika Mindy STROKAPPE, Daphné TRUAN
  • Publication number: 20190023745
    Abstract: The present invention methods and compositions for treating a Zika virus infection in a subject, comprising administering to the subject an effective amount of an antibody against Zika virus and/or an epitope that induces an immune response to Zika virus.
    Type: Application
    Filed: July 19, 2018
    Publication date: January 24, 2019
    Inventors: Ralph Baric, Jessica A. Plante, Jesica Swanstrom, Matthew Begley
  • Publication number: 20190023746
    Abstract: The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain.
    Type: Application
    Filed: August 2, 2018
    Publication date: January 24, 2019
    Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
  • Publication number: 20190023747
    Abstract: Vaccination methods to control PCV2 infection with different PCV2 subtypes are disclosed. Specifically, a PCV2 subtype b (PCV2b) ORF2 proteins or immunogenic compositions comprising a PCV2b ORF2 protein are used in a method for the treatment or prevention of an infection with PCV2 of the same PCV2b and/or different subtype; the reduction, prevention or treatment of clinical signs caused by an infection with PCV2 of the same PCV2b or a different subtype; and/or the prevention or treatment of a disease caused by an infection with PCV2 of the same PCV2b and/or a different subtype. The present invention in particular relates to PCV2 subtype b (PCV2b) ORF2 proteins characterized in that they contain at least one mutation in the BC loop that such that the expressed protein is preferably expressed in a higher amount compared to a PCV2 ORF2 protein that does not contain such mutation.
    Type: Application
    Filed: October 8, 2018
    Publication date: January 24, 2019
    Inventors: Luis Alejandro Hernandez, Christine Margaret Muehlenthaler, Eric Martin Vaughn, Gregory Haiwick
  • Publication number: 20190023748
    Abstract: Disclosed are D-peptide compositions and methods for inhibiting HIV entry into host cells.
    Type: Application
    Filed: January 6, 2017
    Publication date: January 24, 2019
    Inventors: Brett D. WELCH, James Nicholas FRANCIS, Michael S. KAY
  • Publication number: 20190023749
    Abstract: The present invention relates to an RhtB (homoserine/homoserine lactone export transporter) protein variant having an enhanced ability to export O-phosphoserine (OPS) that is a precursor of L-cysteine, a polynucleotide encoding the protein, a vector comprising the polynucleotide, an OPS-producing microorganism comprising the protein variant, a method of producing O-phosphoserine using the microorganism, and a method for preparing cysteine or its derivatives, which comprises reacting O-phosphoserine, produced by the method above, with a sulfide in the presence of O-phosphoserine sulfhydrylase (OPSS) or a microorganism that expresses OPSS.
    Type: Application
    Filed: October 10, 2018
    Publication date: January 24, 2019
    Applicant: CJ CHEILJEDANG CORPORATION
    Inventors: Sol KIM, Hye Won KIM, Jin Sook CHANG, In Hwa YOO
  • Publication number: 20190023750
    Abstract: Bioactive priming polypeptides are provided that are useful when applied to plants in agricultural formulations. Methods of using the formulations containing the bioactive priming polypeptides are also provided which are applied exogenously to the surface of a plant or a plant cell membrane or endogenously to the interior of a plant or to a plant cell. The bioactive priming polypeptides when applied to a plant, a plant part, or a plant growth medium or a rhizosphere in an area surrounding the plant or the plant part increase growth, yield, health, longevity, productivity, and/or vigor of a plant or a plant part and/or decrease abiotic stress in the plant or the plant part and/or protect the plant or the plant part from disease, insects and/or nematodes, and/or increase the innate immune response of the plant or the plant part and/or change plant architecture.
    Type: Application
    Filed: July 20, 2018
    Publication date: January 24, 2019
    Inventors: Brian Thompson, Michelle Leslie
  • Publication number: 20190023751
    Abstract: The present invention relates to isolated polypeptides having cellulolytic enhancing activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.
    Type: Application
    Filed: October 10, 2018
    Publication date: January 24, 2019
    Applicant: Novozymes, Inc.
    Inventors: Kimberly Brown, Paul Harris, Elizabeth Zaretsky, Edward Re, Elena Vlasenko, Keith McFarland, Alfredo Lopez de Leon
  • Publication number: 20190023752
    Abstract: Yeast having modified chromsomes are provided. The chromosomes are modified such that at least one of yeast histones H3, H4, H2A or H2B are fully or partially replaced by their human histone counterparts H3, H4, H2A or H2B, respectively. Histone amino acid substitutions are included. Cell fusions with the yeast having the modified chromosomes and non-yeast cells are provided. Methods for screening test agents using the yeast are also provided. Yeast with a mutated yeast DAD1 gene, the mutated DAD1 gene encoding an E50D mutation in yeast DAD1 protein, are provided, and provide a useful genetic background for making the yeast with partially or fully replaced histone(s).
    Type: Application
    Filed: July 23, 2018
    Publication date: January 24, 2019
    Inventors: David M. Truong, Jef D. Boeke
  • Publication number: 20190023753
    Abstract: This disclosure provides plants having enhanced traits such as increased yield, increased nitrogen use efficiency and increased water use efficiency; propagules, progeny and field crops of such transgenic plants; and methods of making and using such transgenic plants. This disclosure also provides methods of producing hybrid seed from such transgenic plants, growing such seed and selecting progeny plants with the composition or with enhanced traits.
    Type: Application
    Filed: March 26, 2018
    Publication date: January 24, 2019
    Inventors: Mark S. Abad, Paul S. Chomet, Dhanalakshmi Ramachandra, Tyamagondlu V. Venkatesh, Xiaoyun Wu
  • Publication number: 20190023754
    Abstract: Methods for treating cancer with a stabilized BCL9 peptide are encompassed, wherein the stabilized peptide comprises a portion of the HD2 domain of the BCL9 protein containing a hydrocarbon crosslinker generated using ?, ?-disubstituted amino acids.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 24, 2019
    Inventor: David ZHU
  • Publication number: 20190023755
    Abstract: The invention provides peptides and analogs of INGAP and HIP peptides. The peptides and analogs can be used in methods for treating various diseases and conditions. Such diseases and conditions can include impaired pancreatic function, treating a metabolic disease, for example, diabetes, both type 1 and type 2 diabetes, islets induction, expansion and proliferation for transplantation, promoting neuroprotection or nerve regeneration, promoting liver regeneration or inhibiting inflammation.
    Type: Application
    Filed: May 29, 2018
    Publication date: January 24, 2019
    Inventors: Liping Liu, Ru Bai